3192 results for «600»
3192 results
TAV-in-TAV
08 Feb 2025 – From PCR Tokyo Valves 2025
Watch this PCR Tokyo Valves 2025 session on TAV-in-TAV to discover essential insights on optimizing the procedure. Learn how CT analysis and precise measurements are critical for success, and why coronary protection, chimney stenting, and leaflet modification must be considered in high-risk cases. Experts discuss key...
Novel Hertz Contact intravascular lithotripsy: calcium fragmentation with zero trade-offs
27 Feb 2026 – From Euro4C Annual Meeting
This session introduces the novel Hertz Contact intravascular lithotripsy system, designed for effective calcium fragmentation without trade-offs. It covers lesion types amenable to treatment, system mechanism, optimization tips, and discusses real-world cases along with supporting clinical trial evidence.
Mastering techniques from basic to complex - Avoidance and management of TAVI complications
13 Feb 2026 – From PCR Tokyo Valves 2026
Address the challenges posed by complex TAVI complications through expert discussion on prevention, management, and bailout techniques. This session covers critical complications such as annulus rupture, stroke, conduction disturbances, and vascular events.
Mastering techniques from basic to complex - Advanced TAVI
13 Feb 2026 – From PCR Tokyo Valves 2026
Explore advanced TAVI topics including valve selection for small annuli, optimization strategies for bicuspid aortic valve interventions, and techniques ensuring safety and efficacy in valve-in-valve procedures.
How to avoid and manage complications
28 Feb 2026 – From Euro4C Annual Meeting 2026
Build a comprehensive complication-management toolbox tailored for PCI in heavily calcified vessels. This session covers prevention and management techniques for complications arising from severely calcified lesions, illustrated by practical cases and expert insights into risky lesions and challenging devices.
Drug-eluting balloon in calcified lesions and complex lesions
28 Feb 2026 – From Euro4C Annual Meeting 2026
This session explores the application of drug-eluting balloons (DCB) in managing calcified and complex coronary lesions. Emphasis is placed on identifying appropriate lesions for a DCB-only strategy, the critical role of vessel preparation prior to drug delivery, and the long-term physiological assessment following treatment, supported by...
Closing Ceremony
28 Feb 2026 – From Euro4C Annual Meeting 2026
The closing ceremony marks the conclusion of the conference, providing a summary of key learnings, acknowledgments, and final reflections on the advancements and discussions presented throughout the event.
Imaging-guided intravascular lithotripsy for calcified lesions - LIVE case
27 Feb 2026 – From Euro4C Annual Meeting 2026
This live educational case from St. Francis Hospital and Heart Center demonstrates imaging-guided intravascular lithotripsy for calcified lesions. It covers lesion selection criteria, preparation and delivery of lithotripsy catheters, and reviews recent clinical evidence to guide best practices.
LIVE Educational Case from St. Francis Hospital & Heart...
Primary Outcomes of a Pivotal Multicenter Randomized Trial Comparing the AGENT Paclitaxel-Coated Ballon with Conventional Ballon Angioplasty for In-Stent Restenosis (AGENT IDE)
27 Oct 2023
Mirvat Alasnag provides her take on the AGENT IDE trial which was presented by Robert W. Yeh at TCT Congress 2023. This pivotal randomized trial compares the safety and efficacy of the AGENT DCB to conventional balloon angioplasty in patients with ISR. It is the first...
Author
The greatest advance in the next 40 years would be to remove the need for angioplasty
17 May 2017
Spencer B. King performed some of the first coronary angioplasty procedures in the USA—having recently received a thank-you from the first patient that he treated. He tells The Daily Wire that the steerable guidewire, rather than the stent, was the greatest advance in angioplasty and that...
Authors :
COVID-19 vaccines: Burning questions from the community and real-world applicability
13 Jan 2021
View a number of questions of interest to the interventional cardiovascular community, as well as the real-world applicability of COVID-19 vaccine trials.
The AQUATIC trial: Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation
01 Sep 2025
Chiara De Biase provides her take on the results of AQUATIC presented by Martine Gilard at ESC Congress 2025 in Madrid.
Author
![The AQUATIC trial [Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation: Rationale for and design of the AQUATIC double-blind randomized trial]](https://www.pcronline.com/var/pcrov3/storage/images/pcronline/news/congress-coverages/esc/2025/aquatic-trial-quitting-versus-using-aspirin-therapy-patients-stabilized-cad-stenting-long-term-oral-anticoagulation/27448089-9-eng-GB/The-AQUATIC-trial-Assessment-of-quitting-versus-using-aspirin-therapy-in-patients-with-stabilized-coronary-artery-disease-after-stenting-who-requi_image_responsive_6.jpg)